Finanzen von Aytu Biopharma Inc (AYTU)AYTUAytu Biopharma Inc

Aytu Biopharma Inc (AYTU) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is ADHD portfolio, accounting for 64.3% of total sales, equivalent to $10.36M. Other significant revenue streams include EXXUA and Pediatric portfolio. Understanding this composition is critical for investors evaluating how AYTU navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Aytu Biopharma Inc maintains a gross margin of 59.90%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4.82%, while the net margin is -0.09%. These profitability ratios, combined with a Return on Equity (ROE) of -52.55%, provide a clear picture of how effectively AYTU converts its operational activities into shareholder value.

In the context of the broader market, AYTU competes directly with industry leaders such as TXMD and ATOS. With a market capitalization of $20.11M, it holds a significant position in the sector. When comparing efficiency, AYTU's gross margin of 59.90% stands against TXMD's 100.00% and ATOS's N/A. Such benchmarking helps identify whether Aytu Biopharma Inc is trading at a premium or discount relative to its financial performance.

The company reported total net revenue of $16.1 million in Q4 FY2026, a 6% increase from the previous year, but has also experienced significant net losses, including a net loss of $5.6 million in Q3 2026. Gross margins have been relatively stable, around 59.90% in Q4 2026, but the overall financial performance remains inconsistent.